X4 Pharmaceuticals (XFOR) Short term Debt (2017 - 2023)

X4 Pharmaceuticals has reported Short term Debt for 6 years, with the latest figure at $764000.0 in Q2 2023.

• For the quarter ending Q2 2023, Short term Debt fell 91.12% year-over-year to $764000.0; the trailing twelve-month figure through Jun 2023 stood at $764000.0 (down 91.12% YoY), and the FY2022 full-year result was $1.3 million, up 65.41% from the prior year.
• Short term Debt for Q2 2023 stood at $764000.0, up from $554000.0 in the prior quarter.
• The five-year high for Short term Debt was $14.6 million in Q3 2022, with the low at $554000.0 in Q1 2023.
• Historically, Short term Debt has averaged $4.0 million across 4 years, with a median of $2.4 million in 2022.
• Annual changes were most pronounced in 2022 — Short term Debt jumped 2009.81% — and 2023, when it slumped 91.12%.
• X4 Pharmaceuticals' Short term Debt stood at $4.2 million in 2019, then slumped by 80.85% to $795000.0 in 2021, then soared by 65.41% to $1.3 million in 2022, then tumbled by 41.9% to $764000.0 in 2023.
• The last three Short term Debt figures came in at $764000.0 (Q2 2023), $554000.0 (Q1 2023), and $1.3 million (Q4 2022), per Business Quant data.